Following this activity, participants should be able to: (1) Identify the risk factors associated with the histologic transformation of indolent B-cell lymphomas. (2) Review evidence from clinical trials supporting the use of novel treatment options for transformed indolent B-cell lymphomas. (3) Develop an individualized treatment plan for patients with transformed indolent B-cell lymphomas.
- Provider:National Comprehensive Cancer Network
- Activity Link: https://education.nccn.org/node/95330
- Start Date: 2024-06-05 05:00:00
- End Date: 2024-06-05 05:00:00
- Credit Details: AAPA Category 1 Credit™️: 1.0 hours
AMA PRA Category 1 Credit™️: 1.0 hours
Optometry: 1.0 hours
Pharmacy: 1.0 hours - Commercial Support: Source: AstraZeneca (Any division) - Amount: 0.0 - Is Kind Support: False Source: Exelixis - Amount: 0.0 - Is Kind Support: False Source: GlaxoSmithKline - Amount: 0.0 - Is Kind Support: False Source: Lantheus - Amount: 0.0 - Is Kind Support: False Source: Merck (Any division) - Amount: 0.0 - Is Kind Support: False Source: Novartis Corporation Pharmaceuticals - Amount: 0.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence, Learner/Team Performance
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest